AKBA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Akebia Therapeutics Inc (AKBA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive revenue growth and potential for future expansion, the recent insider selling, lack of strong technical signals, and mixed financial performance suggest that it is better to hold off on investing until clearer positive catalysts emerge.
The technical indicators for AKBA are mixed. The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 60.37, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its pivot level of 1.323, with resistance at 1.499 and support at 1.147. Overall, the technical outlook does not strongly favor a buy.
Akebia expects significant revenue growth for Vafseo by 2026, driven by expanded access and improved adherence rates.
Revenue grew 23.9% YoY in Q4 2025, with total net product revenue of $227 million for
Gross margin increased to 81.66%, up 28.44% YoY.
Insiders are selling, with a 248% increase in selling activity over the last month.
Q4 GAAP EPS of -$0.05 missed expectations, and net income dropped significantly YoY.
Analysts have lowered price targets recently due to inventory issues and lower-than-expected revenue for Vafseo.
In Q3 2025, revenue increased by 57.01% YoY to $58.77 million, but net income dropped by -102.69% YoY to $540,000. EPS fell to 0, down -100% YoY. Gross margin improved significantly to 81.66%, up 28.44% YoY. While revenue growth is strong, profitability metrics have deteriorated.
Analysts maintain a Buy/Overweight rating but have lowered price targets recently (from $5 to $4 and $6 to $4) due to inventory and revenue challenges. This reflects cautious optimism but highlights near-term risks.
